Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model

International Journal of Cancer

Volumn 129, Issue 4, 2011, Pages 870-878

  Hoeben, Bianca A W ^a   Molkenboer Kuenen, Janneke D M ^a   Oyen, Wim J G ^a   Peeters, Wenny J M ^a   Kaanders, Johannes H A M ^a   Bussink, Johan ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

antibody; cetuximab; head and neck cancer; preclinical imaging; SPECT

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; INDIUM 111; PENTETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CANCER CELL CULTURE; CELL STRAIN FADU; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; HEAD AND NECK CARCINOMA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FLUORESCENT ANTIBODY TECHNIQUE; HEAD AND NECK NEOPLASMS; IMMUNOENZYME TECHNIQUES; INDIUM RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, NUDE; PENTETIC ACID; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959708966     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25727     Document Type: Article

References (42)

1. Herbst RS,. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59: 21-6. (Pubitemid 38610223)
2. Bussink J, Kaanders JH, van der Kogel AJ,. Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy. Radiother Oncol 2007; 82: 10-7. (Pubitemid 46097129)
3. Bussink J, van der Kogel AJ, Kaanders JH,. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008; 9: 288-96. (Pubitemid 351722948)
4. Nicholson RI, Gee JM, Harper ME,. EGFR and cancer prognosis. Eur J Cancer 2001; 37 (Suppl 4): S9-15. (Pubitemid 32938124)
5. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L,. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-6. (Pubitemid 36025259)
6. Sunada H, Magun BE, Mendelsohn J, MacLeod CL,. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 1986; 83: 3825-9. (Pubitemid 16062376)
7. Meyerhardt JA, Mayer RJ,. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-87.
8. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-27.
9. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78. (Pubitemid 43209104)
10. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-8.
11. Bussink J, van Herpen CM, Kaanders JH, Oyen WJ,. PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol 2010; 11: 661-9.
12. Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW,. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab. Eur J Nucl Med Mol Imaging 2010; 37: 1368-76.
13. Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, Lambin P,. Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET. J Nucl Med 2009; 50: 123-31.
14. Cai W, Chen K, He L, Cao Q, Koong A, Chen X,. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007; 34: 850-8. (Pubitemid 46798960)
15. Ping Li W, Meyer LA, Capretto DA, Sherman CD, Anderson CJ,. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm 2008; 23: 158-71. (Pubitemid 351630188)
16. Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel MW,. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 2008; 23: 619-31.
17. Barrett T, Koyama Y, Hama Y, Ravizzini G, Shin IS, Jang BS, Paik CH, Urano Y, Choyke PL, Kobayashi H,. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res 2007; 13: 6639-48. (Pubitemid 350206799)
18. Niu G, Li Z, Xie J, Le QT, Chen X,. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 2009; 50: 1116-23.
19. Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, Gambhir SS, Chen X,. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res 2010; 16: 2095-105.
20. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM, Mendelsohn J,. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991; 83: 97-104.
21. Schechter NR, Wendt RE, III, Yang DJ, Azhdarinia A, Erwin WD, Stachowiak AM, Broemeling LD, Kim EE, Cox JD, Podoloff DA, Ang KK,. Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2004; 45: 1683-7. (Pubitemid 47618475)
22. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM,. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 1993; 37: 343-9. (Pubitemid 23300519)
23. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J,. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311-8.
24. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Versleijen-Jonkers YM, Oyen WJ, van der Graaf WT, Boerman OC,. ImmunoSPECT and immunoPET imaging of IGF-1R expression with radiolabeled R1507 in a triple negative breast cancer model. J Nucl Med 2010; 51: 1565-72.
25. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA, Jr,. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72: 77-89. (Pubitemid 14091996)
26. Koenig JA, Kaur R, Dodgeon I, Edwardson JM, Humphrey PP,. Fates of endocytosed somatostatin sst2 receptors and associated agonists. Biochem J 1998; 336 (Pt 2): 291-8. (Pubitemid 28564383)
27. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM,. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-11. (Pubitemid 40544648)
28. Thevenaz P, Ruttimann UE, Unser M,. A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process 1998; 7: 27-41. (Pubitemid 128745320)
29. Hoeben BA, Kaanders JH, Franssen GM, Troost EG, Rijken PF, Oosterwijk E, van Dongen GA, Oyen WJ, Boerman OC, Bussink J,. PET of Hypoxia with 89Zr-Labeled cG250-F(ab')2 in Head and Neck Tumors. J Nucl Med 2010; 51: 1076-83.
30. van der Have F, Vastenhouw B, Ramakers RM, Branderhorst W, Krah JO, Ji C, Staelens SG, Beekman FJ,. U-SPECT-II: An ultra-high-resolution device for molecular small-animal imaging. J Nucl Med 2009; 50: 599-605.
31. Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, de Mulder PH, Corstens FH, Mulders PF, Oyen WJ,. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res 2003; 9: 3953S-60S. (Pubitemid 37169202)
32. Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ,. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med 2008; 49: 1472-9.
33. Goldenberg A, Masui H, Divgi C, Kamrath H, Pentlow K, Mendelsohn J,. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst 1989; 81: 1616-25. (Pubitemid 19264044)
34. Brouwers A, Mulders P, Oosterwijk E, Buijs W, Corstens F, Oyen W, Boerman C,. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. Cancer Biother Radiopharm 2004; 19: 466-77. (Pubitemid 39281337)
35. Nordberg E, Orlova A, Friedman M, Tolmachev V, Stahl S, Nilsson FY, Glimelius B, Carlsson J,. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR-expressing tumour cells. Oncol Rep 2008; 19: 853-7. (Pubitemid 351802651)
36. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Nanni C, Boschi S, Lodi F, Nicoletti G, Landuzzi L, Lollini PL, Biasco G,. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann Oncol 2009; 20: 213-26.
37. Xu N, Cai G, Ye W, Wang X, Li Y, Zhao P, Zhang A, Zhang R, Cao B,. Molecular imaging application of radioiodinated anti-EGFR human Fab to EGFR-overexpressing tumor xenografts. Anticancer Res 2009; 29: 4005-11.
38. Kareem H, Sandstrom K, Elia R, Gedda L, Anniko M, Lundqvist H, Nestor M,. Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF. Tumor Biol 2010; 31: 79-87.
39. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12: 5064-73. (Pubitemid 44453332)
40. Patel D, Lahiji A, Patel S, Franklin M, Jimenez X, Hicklin DJ, Kang X,. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res 2007; 27: 3355-66. (Pubitemid 47607562)
41. Aerts HJ, Dubois L, Hackeng TM, Straathof R, Chiu RK, Lieuwes NG, Jutten B, Weppler SA, Lammering G, Wouters BG, Lambin P,. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII. Radiother Oncol 2007; 83: 326-32. (Pubitemid 46907977)
42. Vallis KA, Reilly RM, Chen P, Oza A, Hendler A, Cameron R, Hershkop M, Iznaga-Escobar N, Ramos-Suzarte M, Keane P,. A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor. Nucl Med Commun 2002; 23: 1155-64. (Pubitemid 36026976)